Epstein Secrets

shares are deposits or other obligations of a bank or are insured by the Federal Deposit lose Corporation or any other governmental agency. Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of the depositary shares or Preferred Stock or determined that this prospectus suppl

tements and management' s assessment of the effectiveness of internal control over financial reporting (which is included in Management' s Report on Internal Control over Financial Reporting) incorporated in this prospectus supplement by reference to the Annual Report on Form 10-K of JPMorgan Chase for the year ended

the fiscal year ended March 31, 2018 , included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2018 , as filed with the U.S. Securities and Exchange Commission ("SEC"). NOTE 2 — FIELD-FOR-SALE AND DISCONTINUED OPERATIONS Subsequent to the current period's balance sheet date of June 30, 2018 the Company and

13,274,261 %change from base amount (1.29)% 1.58% change from base amount (169,025) $ $ 206,575 Item 4. Controls and Pmeralares Changes in Internal Control over Financial Reporting There were no changes to our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Se

offering price. less the underwriting discount. within 30 days from the date of this prospectus supplement solely to cover over-allotments. None of the Securities and Exchange Commission, any state securities commission, the Registrar of Companies in Bermuda, the Bermuda Monetary Authority or any other regulatory body has approved or

schedules and management's assessment of the effectiveness of internal control over financial reporting (which is included in Management's Report on Internal Control over Financial Reporting) incorporated in this Prospectus by reference to the Annual Report on Form 10-K of Validus Holdings, Ltd. for the year ended Dec